Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission-Reference-Cited by-同舟云学术

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission

Published:2019-06-14 Issue:12 Volume:3 Page:1826-1836
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Rashidi Armin¹^ORCID,Hamadani Mehdi²^ORCID,Zhang Mei-Jie²³,Wang Hai-Lin²,Abdel-Azim Hisham⁴,Aljurf Mahmoud⁵,Assal Amer⁶^ORCID,Bajel Ashish⁷,Bashey Asad⁸,Battiwalla Minoo⁹,Beitinjaneh Amer M.¹⁰,Bejanyan Nelli¹¹,Bhatt Vijaya Raj¹²,Bolaños-Meade Javier¹³,Byrne Michael¹⁴,Cahn Jean-Yves¹⁵,Cairo Mitchell¹⁶,Ciurea Stefan¹⁷,Copelan Edward¹⁸,Cutler Corey¹⁹,Daly Andrew²⁰,Diaz Miguel-Angel²¹,Farhadfar Nosha²²,Gale Robert P.²³^ORCID,Ganguly Siddhartha²⁴,Grunwald Michael R.¹⁸,Hahn Theresa²⁵,Hashmi Shahrukh⁵²⁶^ORCID,Hildebrandt Gerhard C.²⁷^ORCID,Holland H. Kent⁸,Hossain Nasheed²⁸,Kanakry Christopher G.²⁹,Kharfan-Dabaja Mohamed A.³⁰,Khera Nandita³¹,Koc Yener³²,Lazarus Hillard M.³³,Lee Jong-Wook³⁴,Maertens Johan³⁵,Martino Rodrigo³⁶,McGuirk Joseph²⁴^ORCID,Munker Reinhold³⁷,Murthy Hemant S.²²^ORCID,Nakamura Ryotaro³⁸,Nathan Sunita³⁹,Nishihori Taiga⁴⁰^ORCID,Palmisiano Neil⁴¹,Patel Sagar⁴²^ORCID,Pidala Joseph⁴³,Olin Rebecca⁴⁴,Olsson Richard F.⁴⁵⁴⁶^ORCID,Oran Betul⁴⁷,Ringden Olov⁴⁸^ORCID,Rizzieri David⁴⁹,Rowe Jacob⁵⁰,Savoie Mary Lynn²⁰^ORCID,Schultz Kirk R.⁵¹,Seo Sachiko⁵²,Shaffer Brian C.⁵³,Singh Anurag²⁴,Solh Melhem⁸,Stockerl-Goldstein Keith⁵⁴,Verdonck Leo F.⁵⁵,Wagner John⁴¹^ORCID,Waller Edmund K.⁵⁶^ORCID,De Lima Marcos⁵⁷,Sandmaier Brenda M.⁵⁸^ORCID,Litzow Mark⁵⁹^ORCID,Weisdorf Dan⁶⁰^ORCID,Romee Rizwan¹⁹,Saber Wael²

Affiliation:

1. Department of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN;

2. Center for International Blood and Marrow Transplant Research, Department of Medicine, and

3. Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI;

4. Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA;

5. Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia;

6. NYPH/Columbia University Medical Center, New York, NY;

7. Royal Melbourne Hospital City Campus, Parkville, VIC, Australia;

8. The Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA;

9. Hematology Branch, Sarah Cannon BMT Program, Nashville, TN;

10. University of Miami, Miami, FL;

11. Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Minneapolis, MN;

12. The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE;

13. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD;

14. Vanderbilt University Medical Center, Nashville, TN;

15. Department of Hematology, CHU Grenoble Alpes, Grenoble, France;

16. Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY;

17. MD Anderson Cancer Center, Houston, TX;

18. Levine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC;

19. Dana-Farber Cancer Institute, Boston, MA;

20. Tom Baker Cancer Center, Calgary, AB, Canada;

21. Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain;

22. Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL;

23. Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom;

24. University of Kansas, Westwood, KS;

25. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY;

26. Department of Internal Medicine, Mayo Clinic, Rochester, MN;

27. Markey Cancer Center, University of Kentucky, Lexington, KY;

28. Loyola University Chicago Stritch School of Medicine, Maywood IL;

29. Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;

30. Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL;

31. Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ;

32. Medical Park Hospital, Antalya, Turkey;

33. Case Western Reserve University, Cleveland, OH;

34. Division of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea;

35. University Hospital Gasthuisberg, Leuven, Belgium;

36. Divison of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;

37. Section of Hematology/Oncology, Department of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA;

38. Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;

39. Rush University Medical Center, Chicago, IL;

40. Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

41. Thomas Jefferson University Hospital, Philadelphia, PA;

42. Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH;

43. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

44. University of California San Francisco Medical Center, San Francisco, CA;

45. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;

46. Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden;

47. Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX;

48. Translational Cell Therapy Research, Clintec, Karolinska Institutet, Stockholm, Sweden;

49. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC;

50. Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel;

51. Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia Children's Hospital, The University of British Columbia, Vancouver, BC, Canada;

52. Department of Hematology and Oncology, Dokkyo Medical University. Mibu, Japan;

53. Memorial Sloan Kettering Cancer Center, New York, NY;

54. Barnes Jewish Hospital, St. Louis, MO;

55. Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands;

56. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;

57. Department of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH;

58. Division of Medical Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

59. Division of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN; and

60. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN

Abstract

Abstract HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy–based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease–donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy–based Haplo-HCT vs MSD using calcineurin inhibitor–based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/12/1826/1555025/advancesadv2019000050.pdf

Reference30 articles.

1. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings;Szydlo;J Clin Oncol,1997

2. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN);Howard;Biol Blood Marrow Transplant,2015

3. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults;Kasamon;J Clin Oncol,2015

4. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide;Bashey;J Clin Oncol,2017

5. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine;Giannotti;J Hematol Oncol,2018

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of CD34 positive cell dose in donor graft on the outcomes after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide – A retrospective single-center study with a Japanese cohort;Blood Cells, Molecules, and Diseases;2024-03

2. The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia;Bone Marrow Transplantation;2024-02-06

3. Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene;Journal of Pediatric Hematology/Oncology;2024-02-01

4. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation;Transplantation and Cellular Therapy;2024-02

5. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide;Transplantation and Cellular Therapy;2024-02